In Aug 2025, Taiwan FDA approved Calgent’s IND application to initiate the Phase I clinical trials for CAL056 (Fiberfate) in healthy volunteers. In Nov 2025, Calgent began recruiting subjects for its phase I clinical trial in Taiwan, marking a new milestone.
